Beta Thalassemia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of beta thalassemia (BT) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of beta thalassemia for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s beta thalassemia forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of beta thalassemia?
- Of all people with beta thalassemia, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of beta thalassemia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 30 beta thalassemia patient populations, as follows:
- Diagnosed BT prevalent cases.
- Diagnosed BT major prevalent cases.
- Diagnosed BT intermedia prevalent cases.
- Diagnosed B0/B0 BT major prevalent cases.
- Diagnosed B0/B+ BT major prevalent cases.
- Diagnosed B+/B+ BT major prevalent cases.
- Diagnosed B0/B0 BT major prevalent cases with matched related HSC transplantation – younger than 12 years old.
- Diagnosed B0/B0 BT major prevalent cases with matched related HSC transplantation – 12 years of age or older.
- Diagnosed B0/B0 BT prevalent cases without matched related HSC transplantation – younger than 12 years old.
- Diagnosed B0/B0 BT prevalent cases without matched related HSC transplantation – 12 years of age or older.
- Diagnosed BT intermedia prevalent cases requiring transfusions.
- Diagnosed BT major pediatric prevalent cases.
- Diagnosed BT major adult prevalent cases.
- … and many more (details available on request).
Note: coverage may vary by country.
Table of contents
- Beta Thalassemia - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in / excluded from the analyses of beta thalassemia)
- Diagnosed prevalence of beta thalassemia
- Beta thalassemia by severity
- Beta thalassemia major by genotype
- Diagnosed prevalent cases of beta thalassemia major by HSC transplantation
- Diagnosed prevalent cases of beta thalassemia intermedia by the need for transfusion
- Drug-treated cases of beta thalassemia
- Risk / protective factors applied to disease forecast models
- Reference materials
Deepika Chauhan, M.P.H., Epidemiologist, Epidemiology. Her focus is on oncology indications such as non-small-cell lung cancer, colorectal cancer, and gastric cancer. Prior to this role, she was an intern with DRG Analytics, where she worked with cross-functional teams to deliver analytical solutions to clients. Ms. Chauhan also worked at Drexel University as a research assistant on the EPA’s project to prevent Legionnaire’s disease in residential buildings. She graduated with an M.P.H. degree in epidemiology from Drexel University and holds a bachelor’s degree in medicine.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.